NRC HEALTH (NRC) Form 10-Q — Nov 4, 2026
NRC Health reported Q3 2026 revenue of $38.4 million, up 11% year over year, with net income of $4.7 million and diluted EPS of $0.21 versus $0.18 a year ago. Growth was driven by a $3.2 million increase in recurring revenue from existing customers, and total recurring contract value rose 9% to $154.1 million. For the first nine months, revenue rose 6% to $108.6 million, but operating income fell 37% to $11.2 million, weighed down by roughly $8.8 million of non-cash stock compensation tied to executive equity award amendments and $3.2 million of management transition costs, both of which the company says should not recur.
Key figures
- Eps
- 0.21
- Revenue
- 38399000
- Net Income
- 4704000
- Total Assets
- 139213000
- Cash Position
- 3626000
- Shares Outstanding
- 21221538
- Q3 buybacks
- 16700000
- Nine month revenue
- 108594000
- Operating margin q3
- 0.23
- Nine month net income
- 4643000
- Q3 revenue prior year
- 34608000
- Delayed draw term loan
- 91190000
- Free cash flow nine month
- 12390000
- Adjusted ebitda nine month
- 29714000
- Revolving loan outstanding
- 12000000
- Total recurring contract value
- 154090000
- Buyback authorization remaining
- 34003680
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.